Tenaya Therapeutics Announces Proposed Public Offering

Company Overview - Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering potentially curative therapies for heart disease [5] - The company employs integrated capabilities such as target validation, capsid engineering, and manufacturing to create genetic medicines for both rare genetic disorders and common heart conditions [5] Proposed Offering - Tenaya intends to offer and sell units consisting of common stock and Series A and Series B warrants, which allow the purchase of common stock [1] - The offering may also include pre-funded units with pre-funded warrants at a purchase price of $0.001 per share, which will be immediately exercisable and will not expire [1] - The offering is subject to market conditions, and there is no assurance regarding its completion or the actual size and terms [1] Management and Regulatory Aspects - Leerink Partners and Piper Sandler are acting as joint bookrunning managers for the proposed offering [2] - The offering is being conducted under a Registration Statement on Form S-3, previously filed and declared effective by the SEC [2] Pipeline and Product Development - Tenaya's pipeline includes several gene therapies: TN-201 for MYBPC3-associated hypertrophic cardiomyopathy, TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, and TN-301, a small molecule HDAC6 inhibitor for heart failure with preserved ejection fraction [5] - The company also has multiple early-stage programs in preclinical development [5]